For tumor suppressors such as CDKN2A, TP53, and SMAD4, the aberrant rate increased with a higher nuclear grade, albeit alterations in tumor suppressor genes rarely led to targeted therapy. The gene discussed is CDKN2A; the disease is neoplasm.